Abstract
BackgroundDespite the paradigm shift heralded by immune checkpoint blockade (ICB), only a small proportion of patients have a meaningful response. Dose selection of ICB agents was significantly based on in-silico...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
